CD39 and CD73 Expression in Breast Cancer: CD73 as a Favorable Prognostic Factor in HER2-Positive Tumors

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• CD39 (ectonucleoside triphosphate diphosphohydrolase-1) and CD73 (5'-nucleotidase) are critical enzymes in adenosine metabolism within the tumor microenvironment.
• The CD39-CD73-adenosine pathway plays a significant role in immune suppression and tumor progression.
• Understanding the expression patterns of CD39 and CD73 is crucial for developing targeted breast cancer therapies.

Purpose of the Study:

• To investigate the clinical and prognostic significance of CD39 and CD73 expression in breast cancer patients.
• To determine the association between CD39 and CD73 expression and breast cancer subtypes based on hormone receptor and HER2 status.
• To evaluate the correlation between CD39 and CD73 expression and disease-free survival (DFS).

Main Methods:

• Analysis of 472 primary invasive breast cancer patients treated surgically.
• Utilized tissue microarrays for biomarker immunostaining of CD39 and CD73.
• Assessed expression ratios in breast cancer subgroups and correlated with DFS.

Main Results:

• CD39 expression was higher in estrogen receptor (ER)/progesterone receptor (PR) positive and HER2-negative breast cancer.
• CD73 expression in tumor-infiltrating lymphocytes (TILs) was higher in ER/PR-negative and HER2-positive breast cancer.
• High CD39 expression correlated with lower tumor stage, but not survival. CD73 expression in TILs was linked to lower stage and better DFS in HER2-positive breast cancer.

Conclusions:

• CD39 and CD73 expression patterns vary significantly across different breast cancer subtypes.
• CD73 expression in TILs shows a trend towards a favorable prognosis in HER2-positive breast cancer.
• These findings highlight the differential roles of CD39 and CD73 in breast cancer and suggest potential therapeutic implications.